Phthalate esters such as di(2-ethylhexyl)phthalate (DEHP), which are commonly found in cosmetics and used in flexible plastics distributed by the food, construction and medical products industries, have been classified as anti-androgens. High dose DEHP exposure in utero is associated with decreased androgen levels. However, when administered after birth, low doses of DEHP (e.g., 10 mg/kg body weight) may stimulate androgen production.
INTRODUCTION
Increased incidence of urogenital anomalies in newborn male laboratory animal and wildlife species, including cryptorchidism, hypospadias, and reproductive abnormalities has been reported in association with exposure to chemicals in the environment. These reports have in turn generated public concern that the chemical agents in question may impair human reproductive health Sharpe, 2001) . Phthalates are used as plasticizers in certain infant toys and consumer products (e.g., containers for soaps, shampoos, and perfumes) and medical devices such as tubing and catheters. The most abundant phthalate in the environment is di(2-ethylhexyl)phthalate (DEHP). The Agency for Toxic Substances and Disease Registry (ATSDR) estimates that maximum daily exposure to DEHP for the general population is about 2 mg/day. However, occupational and medical exposures can reach much higher levels (ATSDR., 1993) . For instance, exposure to DEHP from blood transfusions can be as high as 250-300 mg, equivalent to a dose of 3.5-4.3 mg/kg for an adult weighing 70 kg, while doses in infants or children can be much higher (CERHR, 2000) . The possibility that DEHP exerts adverse effects on androgen synthesis and thereby interferes with reproductive tract development in the human male fetus has been raised in light of statistical correlations between the incidence of anomalies such as cryptorchidism and shortened anogenital distance, and serum concentrations of monoethyl-hexylphthalate (MEHP), the primary metabolite of DEHP in vivo (Main et al., 2006; Swan et al., 2005) . These putative adverse effects of DEHP on androgen synthesis and fetal Leydig cell function are consistent with results observed in rodent models (Borch et al., 2006; Borch et al., 2005; Foster et al., 2001; Ljungvall et al., 2005; Main et al., 2006; Parks et al., 2000; Swan et al., 2005; Wang et al., 2004; Wilson et al., 2004) , although it is unclear whether and at what doses phthalates perturb pubertal development in the human male.
Previous animal studies of phthalates were generally conducted with high doses and used short exposure periods. Typically, the doses of DEHP that were analyzed (500 mg/kg body weight and above) are at least 100 times higher than the estimated human daily DEHP exposure, and were associated with decreased T production and lower sperm counts (Foster et al., 2001; Sjoberg et al., 1986a; Sjoberg et al., 1986b) . Translation of the results of controlled high-dose acute studies in rodents to the human exposure risk scenario has been difficult. Acute exposure paradigms do not approximate real-life situations for human populations that may be subjected to prolonged low-level exposures.
We previously observed that, in striking contrast to the high-dose exposures, elevations in T levels occur when rats are treated orally with 10 and 100 mg/kg per day DEHP for 28 days during puberty (Akingbemi et al., 2004a; . Similar results were obtained in rats treated by inhalation with a low dose of DEHP comparable to 10 mg/kg per day of oral treatment (Kurahashi et al., 2005) , and boars exposed intramuscularly to DEHP at 50 mg/kg twice per week (Ljungvall et al., 2005) during puberty. Therefore, the present study was designed to investigate dose-dependent effects of DEHP on pubertal timing and to determine whether Leydig cell steroidogenesis is affected by phthalate in a dosedependent manner. We report that a significant advance occurs in the average age of preputial separation occurs in males that are exposed to a low 10 mg/kg dose of DEHP.
MATERIALS AND METHODS

Effects of DEHP exposures in vivo on pubertal timing
Long-Evans rats (Charles River, Wilmington, MA) were used in these studies because an extensive toxicological database is available for this strain in studies of endocrine disrupters and testicular function (Gray et al., 1999) . The rats were housed in polycarbonate standard cages on softwood bedding at 22±2°C, at a relative humidity of 45-65%, and a 12 hour light/dark cycle. A pelleted standard rodent chow (Pico Irradiated, Fisher Scientific) and tap water via water bottles were available ad libitum. Prior to collection of blood and tissues, the rats were euthanized by placement in a chamber that was pre-charged with CO 2 . All animal procedures were performed in accordance with the policies of The Rockefeller University's Animal Care and Use Committee (Protocol #04059).
Earlier we reported on dose-dependent effects of DEHP (10 to 200 mg/kg) (Akingbemi et al., 2004b; . Accordingly, 10 mg/kg per day DEHP was selected based on our previously determined lowest-observed-effect level (LOEL) in pubertal rats (Akingbemi et al., 2004a; . To expand the dose range further and address the possibility that different phthalate-mediated effects could be seen at the high and low ends of the dose response range, 500 mg/kg or 750 mg/kg per day DEHP was selected based on the previously observed LOEL for androgen inhibition (Foster et al., 2001 ).
Cohorts of 40 male rats from mixed size litters were randomly allocated by body weight into 4 groups (N = 10/group). Rats were gavaged with DEHP (10, 500 or 750 mg/kg) or the corn oil vehicle (control) daily, from postnatal day (PND) 21, i.e., at weaning, to day 48. This age interval was used because the pre-pubertal period is a time of active reproductive tract development, and hormonally active chemicals are known to exhibit greater potency during sexual differentiation in rodents and humans than at later times.
Body weight and preputial separation (an index of pubertal onset) were recorded. The observers were blinded to treatment condition to avoid bias. At the end of treatment, animals were killed and blood was collected for determination of serum hormone (LH and T) concentrations. The weights of androgen-dependent tissues such as seminal vesicles and prostates were also measured in selected experiments, and all experiments were repeated at least twice, and the final sample sizes are presented in the results.
Preputial Separation Assay
To assess the effect of chronic DEHP exposures on male preputial separation, male prepubertal Long-Evans rats were assigned to different groups as above. Preputial separation, an easily scored external sign of sexual development in male rats, can be used as an index of change in peripubertal androgen secretion (Korenbrot et al., 1977) . The separation of the prepuce from the glans penis, termed preputial separation, has been shown to be androgen dependent and to occur around the time of puberty in rats. The average ages of preputial separation are 39~45 days of age, just preceding the appearance of mature sperm in the caput epididymis. In pilot experiments, preputial separation was found to occur before Day 51 and prior to the increase in circulating androgen levels. The time course of the accumulative frequency of rats with preputial separation was calculated.
Short-term exposures to DEHP in vivo on immature Leydig cell function
Previously, we observed that, after gavage with 0, 1, 10, 100, or 200 mg/kg/day DEHP for 14 days from PND 21 -34, the rate of body weight gain, serum hormone (T and LH) levels, and testis and seminal vesicle weights were unaffected in pubertal rats . Similarly, 500 mg/kg/day administered over a more chronic setting of 28 (PND 21 -49) days did not affect these parameters. To address whether compensatory changes in androgen synthesis and feedback suppression of pituitary function were associated with 28-day exposures, the higher dose, 500 mg/kg/day, was also evaluated after a shorter, 14 day exposure during the first half (PND 21 -34) of the 28-day exposure setting. Leydig cell T production was examined in addition to the parameters that were measured after 28-day exposures.
Leydig cell purification
Purified Leydig cells were obtained from the testes of 35-day-old rats by collagenase digestion, followed by Percoll density centrifugation as described previously (Ge & Hardy, 1998) . In an initial purification step, Leydig cells from 49-day-old rats were sedimented in solutions of bovine serum albumin (Salva et al., 2001) . After centrifugation through a 55% continuous Percoll gradient, Leydig cells from 35-day-old rats were harvested at densities between 1.070 and 1.088 g/ml, whereas cells from 49-day-old rats were located at a density corresponding to 1.070 or greater, i.e. to the bottom of the tube. Cell yields were estimated with a hemocytometer, and purity was assessed by histochemical staining for 3βHSD using 0.4 mM etiocholan-3β-ol-17-one as the enzyme substrate (Payne et al., 1980) . Leydig cell preparations were 95-97% enriched for cells that stained intensely for this marker enzyme.
Ex vivo T production by Leydig cells after DEHP exposure in vivo
To measure the rates of T production in spent media, aliquots of 0.2 × 10 6 Leydig cells obtained from 35 -day-old rats were incubated in micro-centrifuge tubes in 1 ml of culture medium. The culture medium consisted of DMEM/F-12 buffered with 14 mM NaHCO 3 , containing 0.1 % BSA and 0.5 mg/ml bovine lipoprotein (Sigma-Aldrich Corp.). Incubations were conducted at 34 C for 3 h using the maximally stimulating dose of 100 ng/ml ovine LH 
Treatment with MEHP in vitro
MEHP is the primary metabolite formed from DEHP in vivo and is the mediator of its effects in cells (Huber et al., 1996) . DEHP is a pro-toxin, metabolized in the gastrointestinal tract to MEHP which is 10 times more potent than the parent compound (Huber et al., 1996) . Therefore, incubation of purified Leydig cells with MEHP was used to assess the consequences of phthalate exposures in vitro. A range of MEHP concentrations were tested (10 -9 to 10 -2 M) in cultures of Leydig cells maintained at 34 C for 18 h. MEHP was added alone or in combination with a 0.5 ng / ml of ovine LH (provided by the National Hormone and Pituitary Program, NIDDK, Bethesda, MD). The cells were incubated in a concentration of 0.5 ng/ml (low concentration) of LH in order to maintain Leydig cell viability, and this dose elicits a 25-50% increase in T production relative to control.
RNA analysis by RT-PCR
Pituitary luteinizing hormone β subunit (Lhb) and androgen receptor (Ar) expression levels were quantified by real-time RT-PCR to assess whether the action of DEHP on T production is direct or indirect. Total RNA was isolated from pituitary glands using Trizol following the manufacturer's instructions (Invitrogen, Carlsbad, CA). The cDNA synthesis step and real-time PCR were performed using a thermocycler (model ABI7900HT Applied Biosystems) as previously described (Yuen et al., 2002) . The RNA levels for the house keeping genes ribosomal protein S11 (Rps11), tubulin (Tuba) and β-actin (Actb) were also assayed in all samples to select one that could be used as an internal control. Lhb and Ar mRNA measurements were normalized using a robust global normalization algorithm. All control crossing threshold (Ct) values were corrected by the median difference in all samples from Actb. All samples were then normalized by the difference from the median Ct of the three corrected control gene Ct levels in each sample, with the value converted to a nominal copy number/cell by assuming 2500 Actb mRNA molecules/cell and an amplification efficiency for all reactions of 93%. The primer sequences used for the assays (5'-to -3') were: Ar sense: TATGGTGAGCGTGGACTTTC, antisense:
GCCCATGCCAGAGAAGTAGT; Lhb sense: CAGTGTGCACCTACCGTGAG, antisense:
GGGGAAGGTCACAGGTCATT; Rps11 sense: CGAGGGCACCTACATAGACA, antisense: GAGATAGTCCCGGCGGATGA; Actb sense: GCCTCAACACCTCAAACCAC, antisense: CCACAGCTGAGAGGGAAATC; Tuba Sense: AGCGCCCAACCTACACTAAC , antisense: GGGAAGTGGATGCGAGGGTA.
Hormone Assays
Serum LH concentrations were measured using 125 I rat LH (Covance Laboratories, Vienna, VA) and materials obtained from the National Hormone and Pituitary Program, namely, rat antibody NIDDK-anti-rLH-S11 (NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases), and LH reference standards (NIDDK-rLF-RP-3). The secondary IgG antiserum was supplied by ICN. The lower limit of detection for this assay is 0.12 ng/ml,
and LH values were expressed in relation to the standards. The intra-and inter-assay coefficients of variation were 5% and 10%, respectively. Steroid hormone (T)
concentrations were measured by a previously described tritium-based RIA validated for use with rat antiserum (Akingbemi et al., 2004a; , The assays were performed in triplicate, and the intra-and inter-assay coefficients of variation were 10%
and 15%, respectively.
Statistics
Data are presented as means ± SEMs. For the in vivo studies, the data represent the averages from two separate experiments, and the data for the in vitro studies were combined from at least three separate experiments. Data were analyzed by one-way ANOVA with Dunnett's Multiple Comparison Test to identify differences between groups (control, 10, 500 and 750 mg/kg DEHP). The time course of the accumulative frequency of rats with preputial separation was fitted by sigmoidal curvilinear regression. The average age at which 50% of the males attained complete preputial separation was calculated.
Data were analyzed by two-way ANOVA with postnatal day (PND) and drug dose as independent measures. Differences were considered significant at P 0.05.
RESULTS
Low dose DEHP exposures advance the timing of preputial separation
The average age of normal rats that had preputial separation was 41.5 ± 0.1 days ( Figure   1 ). After treatment from 21 to 49 days of age, the 10 mg/kg dose of DEHP advanced the onset of puberty, and the average age of treated animals was 39.7 ± 0.1 days (P < 0.05) (Figure 1 ). The external precocity seen in the 10 mg/kg DEHP group was associated with heavier seminal vesicle weights and elevated serum T levels ( Table 1 ). The 500 mg/kg dose of DEHP did not affect the timing of preputial separation (with a mean age of 40.8 ± 0.1, Figure 1 ), but testis weights were reduced (Table 1 ). In contrast, the 750 mg/kg dose delayed puberty, with a mean age of 46.3 ± 0.6 days (P < 0.001) (Figure 1 ), decreased serum T levels and lowered body, testis and prostate weights (Table 1) . Body weights on the day of preputial separation were 204.6 ± 3.34, 202.4 ± 2.8, 200.6 ± 5.6 and 228.8 ± 3.8 g in control and rats treated with 10, 500, and 750 mg/kg DEHP, respectively. The only group that differed from control (P< 0.001) was the 750 mg/kg DEHP exposure. This indicated that the observed advance of preputial separation induced by 10 mg/kg DEHP was not caused by increased body weight. The 750 mg/kg DEHP exposure reduced body weight at the end of treatment, but the body weight in this group was increased relative to control at the time of preputial separation (as would be expected if continued growth occurred during the delay). This indicated that the treatment effect on the timing of preputial separation was not influenced by body weight. These data suggest that elevated serum T levels contributed to precocious preputial separation in the rats that were exposed to the low dose DEHP. Conversely, the decreases in serum T levels, in animals that were exposed to the high 750 mg/kg per day dose of DEHP, were postulated to contribute to the observed delay in preputial separation.
The possibility of an effect of DEHP on the male reproductive axis was also examined by measuring Lhb and Ar mRNA content in the pituitary. DEHP (0-750 mg/kg/day) did not affect pituitary Lhb or Ar mRNA levels (Figure 2 ). These data together with the unchanged serum LH levels indicate that regulation of serum T levels by DEHP is not mediated by an effect on pituitary secretion of LH.
High dose short-term exposures to DEHP inhibit Leydig steroidogenesis
When the 500 mg/kg/day dose was tested for 14 days as shown above, decreases were seen in testis weights and serum T levels. The 500 mg/kg dose of DEHP also decreased T production by Leydig cells in vitro under substrate-saturating conditions (5 µM) of 22(R)-hydroxycholesterol (CHOL) ( Table 2 ), suggesting that inhibition occurs at the step of cholesterol side chain cleavage enzyme activity, and/or later in the T biosynthetic pathway.
Biphasic effect of MEHP on T production in vitro
The above in vivo experiment suggests a direct action of DEHP on Leydig cells. Since DEHP is pro-toxin and MEHP is the primary metabolite formed from DEHP in vivo with 10 times more potency compared to the parent compound (Huber et al., 1996) , a wide range of MEHP concentrations was tested on Leydig cells incubated in vitro. The cells were incubated in the presence and absence of LH (0.5 ng /ml). At 100 µM and 1 mM, MEHP increased LH-stimulated T production, whereas a higher concentration, 10 mM, was inhibitory ( Figure 3 ). Cell viability as assessed by Trypan blue exclusion staining was not affected at any of the doses tested (unpublished observations). In the absence of LH, 1 mM MEHP increased T production although it was 10 times less potent than when combined with LH. This indicated that phthalate effects at low doses might have a direct stimulatory effect on T production.
DISCUSSION
The present study demonstrates that a low dose exposure to DEHP (10 mg/kg) in vivo induces increased serum T levels (Table 1) , precocious two day advancement in the timing of preputial separation (Figure 1) , and increases seminal vesicle weight (Table 1 ). The magnitude of the advance is notable in that the overall duration of puberty in the rat is on the order of 28 days. In contrast, higher doses of DEHP (750 mg/kg per day) had the opposite effect of lowering T levels (Table 1) and delaying puberty (Figure 1 ). These results point to the necessity of considering dose when evaluating the consequences of phthalate exposures. Acceptable human exposures to specific chemicals are calculated by using the no-observed-adverse-effect levels (NOAEL) derived from animal experiments, adjusted by uncertainty factors that account for susceptible populations and interspecies differences (Vaslet et al., 2002) . The NOAEL for DEHP in pubertal rats was previously determined to be 1 mg/kg per day (Akingbemi et al., 2004a; .
It was established previously that during days 21 to 49 of pubertal development, oral exposures to 10 mg/kg per day of DEHP caused Leydig cell hyperplasia and persistently elevated T levels (Akingbemi et al., 2004a) . This observation was confirmed independently in two other studies: rats treated by inhalation with a low dose of DEHP (comparable to an oral dose of 10 mg/kg per day (Kurahashi et al., 2005) , and boars that received DEHP at 50 mg/kg twice a week intramuscularly during puberty had elevated serum T levels (Ljungvall et al., 2005) . In the boar testis, Leydig cell hyperplasia results from low-dose-DEHP-exposures, similar to what has been observed in rats (Ljungvall et al., 2005) . The present observations extend these earlier findings and show that DEHPmediated increases in androgen levels are sufficient to advance the timing of preputial separation. Preputial separation has been shown to be androgen dependent, and we have established that increases in T to adult levels advanced the timing of preputial separation from 41 days to 30 days using T-releasing implants (Hardy unpublished data). Human exposures to DEHP are uncontrolled and are undoubtedly comprised of both low and high dose levels. In this scenario, distinct low and high dose effects may cancel each other, which could explain why, to date, there is a failure to show conclusively that DEHP has anti-androgenic effects in human male infants (Kaiser, 2005) .
Pituitary Lhb and Ar mRNA levels are sensitive to the regulation by of androgen in circulation. Androgen suppresses Lhb expression (Fallest et al., 1995) and increases Ar expression (Okada et al., 2003) . In the present study we did not observe the any effect of phthalate exposure on Lhb or Ar mRNA levels in either low (10 mg/kg) or high dose (500 to 750 mg/kg) conditions that either increased or suppressed serum T levels. This indicates that effects of the DEHP on serum T levels are not mediated through pituitary regulations of Lhb mRNA. An apparent trend toward reduced Lhb mRNA levels at 10 mg/kg was associated with the increased T (and androgen negative feedback) levels at this dose.
Therefore, a direct action of DEHP on Leydig cells has been purposed in the present study. Accordingly, a direct action of DEHP was assessed using the DEHP metabolite,
MEHP. Direct exposure of Leydig cells to a wide range of MEHP concentrations in vitro
clearly demonstrated that this metabolite induced a biphasic effect on T production that was similar to the trend obtained after exposures to DEHP in vivo. Low concentrations (100µM) of MEHP stimulated T production and high concentrations (> 10 mM) were suppressive. The MEHP concentration that was associated with higher rates of T, 100
µM, equates to a serum level of 30 µg/ml, 10 times lower than a 10 mg/kg per day exposure regimen (Akingbemi et al., 2004a) . These results indicate that chronic direct stimulation of Leydig cells by MEHP increases T production. The stimulatory effect of lowdose exposures may take time to develop, as 10 mg/kg/day DEHP did not increase serum T levels at PND 35 in rats treated from PND21 for 14 days (Akingbemi et al., 2004a; ). This latency of the effect on plasma concentration of T was also seen in boars exposed to 50 mg/kg/per day DEHP (Ljungvall et al., 2005) . The direct stimulatory effect of phthalate on T production may contribute to the increase in circulating androgen levels that ensue from low-dose exposures, along with the previously-reported Leydig cell hyperplasia (Akingbemi et al., 2004a; Ljungvall et al., 2005) .
The male reproductive toxicity associated with gestational, prenatal or pubertal exposures to DEHP and other phthalates has largely been documented at doses of 500 mg/kg per day or above (Borch et al., 2005; Foster et al., 2001; Gray et al., 2000; Wilson et al., 2004) .
Of concern is that the inhibitory effects of phthalate exposures on pubertal development can only be achieved at doses of 750 mg/kg per day or higher (Table 1) . Interpretation of the reproductive toxicity of phthalate exposures at doses this high may be confounded by systemic toxicity (Table 1) . The 500 mg/kg dose of DEHP appears to be intermediate, as it did not affect pubertal development or affect serum T concentrations (Table 1) for 28 daytreatment period. However, testis weights and T levels were significantly reduced at 14-day 500 mg/kg DEHP treatment from PND 21 to 34, suggesting that prepubertal rats are more susceptible to inhibition by increased dose of DEHP.
In conclusion, data from the present study show that DEHP has a biphasic effect on Leydig cell function, with low dose exposures increasing T production and advancing the onset of puberty. In contrast, high doses of DEHP are antiandrogenic and delay the onset of puberty. Importantly, these high doses may also be outside the range of real environmental exposure levels and therefore results obtained under such conditions should be considered in this light. 
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